Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00965562
Other study ID # 0001011511
Secondary ID
Status Completed
Phase N/A
First received August 24, 2009
Last updated March 3, 2015
Start date September 2000
Est. completion date October 2010

Study information

Verified date February 2015
Source Donaghue Medical Research Foundation
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of calcium carbonate to fluoxetine in the treatment of moderate to severe PMS. Second, to compare each active agent to a placebo control. Third, to evaluate the efficacy of each treatment for specific symptom clusters (i.e. affective and somatic). Fourth, to determine whether the addition of calcium to on going fluoxetine treatment leads to additional therapeutic benefit.


Description:

This is a double blind, randomized, placebo controlled, parallel study that will randomize 60 women at the Yale site into treatment. Participants will be screened at various collaborating ob-gyn centers for possible PMS symptoms, and direct referrals from the community will also be accepted. Subject participation length is about 7 months with 6 scheduled study visits.

Methodology: After successfully completing the screening and qualification phase, participants will be randomized to treatment at Visit 1 for 5 cycles of double-blind treatment. Participants will be evaluated monthly during the randomization phase for adverse events, concurrent medication, and primary and secondary efficacy variables.


Other known NCT identifiers
  • NCT00683605

Recruitment information / eligibility

Status Completed
Enrollment 49
Est. completion date October 2010
Est. primary completion date June 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 48 Years
Eligibility Inclusion Criteria:

- Female outpatients between the ages of 18 and 48 who are:

- Menstruating

- Meet criteria for moderate to severe PMS

- Report PMS symptoms for at least 9 our of the 12 months prior to screening; 4) *Are using an adequate method of birth control.

Exclusion Criteria:

- Any candidate who:

- Fulfills MINI (DSM-IV) criteria for a serious AXIS 1 disorder

- Fulfills DSM-IV criteria during the charting phase consistent with a diagnosis of psychotic disorder, bipolar disorder or major depressive disorder

- Has a severe, co-existing condition that, in the investigator's opinion, renders the patient unsuitable for the study

- Poses a significant risk of suicide

- Takes ongoing medication that could treat PMS symptoms

- Has a history of hypersensitivity or adverse reaction to fluoxetine or calcium

- Is lactating, pregnant or is planning to become pregnant during the course of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fluoxetine
Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
Calcium
1200 mg of calcium to be taken for 5 menstrual cycles.
Placebo
For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.

Locations

Country Name City State
United States Yale School of Medicine New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Donaghue Medical Research Foundation Yale University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of the Change in IDS Symptom Scores Among Groups IDS = Inventory of Depressive Symptomatology: measures depressive symptoms during the previous premenstrual phase with high internal consistency: sum of responses to 28 of 30 possible items each scored 0 to 3 points with total scoring (0=no symptoms, 84=most severe). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Primary Comparison of the Change in PMTS Symptom Scores Among Groups PMTS = Premenstrual Tension Syndrome (Observer Rating) Scale: a clinician-administered retrospective scale developed for the study of PMS, a sum of responses to 10 items each with 4 points (0=no symptoms, 40=most severe). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Primary Comparison of the Change in CGI-S Symptom Scores Among Groups CGI-S = Clinical Global Impression-Severity: a severity scale widely used in psychopharmacology research (1=normal not at all ill, 7=among most extremely ill). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Primary Comparison of the Change in DRSP Symptom Scores Among Groups DRSP = Daily Record of Severity of Problems, which combines responses to 21 items each with scale: 1=no symptoms, 6=extreme. This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Primary Comparison of the Change in CGI Improvement Scores Among Groups CGI-I = Clinical Global Impression Improvement: the improvement subscale of CGI measuring change at each visit as compared to visit 1 (1=very much improved, 7=very much worse). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Secondary Proportion of Participants With DRSP LOCF Response to Treatment (50% Improvement) DRSP: Daily Record of Severity of Problems, which combines responses to 21 items each with scale: 1=no symptoms, 6=extreme. LOCF: the last observation carried forward. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Secondary Proportion of Participants With IDS LOCF Response to Treatment (50% Improvement) IDS: Inventory of Depressive Symptomatology: measures depressive symptoms during the previous premenstrual phase with high internal consistency: sum of responses to 28 of 30 possible items each scored 0 to 3 points with total scoring (0=least severe, 84=most severe). LOCF: last observation carried forward. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Secondary Proportion of Participants With PMTS LOCF Response to Treatment (50% Improvement) PMTS: Premenstrual Tension Syndrome (Observer Rating) Scale: a clinician-administered retrospective scale developed for the study of PMS, a sum of responses to 10 items each with 4 points (0=no symptoms, 40=most severe). LOCF: last observation carried forward. over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit No
Secondary Proportion of Participants With DRSP Visit-wise Response to Treatment (50% Improvement) Visit-wise response considers participants who remained in the study until Visit 5 and provided data for the visit. DRSP = Daily Record of Severity of Problems, which combines responses to 21 items each with scale: 1=no symptoms, 6=extreme. over duration of treatment from baseline to visit 5, including 4 menstrual cycles averaging 4 months after baseline visit No
Secondary Proportion of Patients With IDS Visit-wise Response to Treatment (50% Improvement) Visit-wise response considers participants who remained in the study until Visit 5 and provided data for the visit.
IDS = Inventory of Depressive Symptomatology: measures depressive symptoms during the previous premenstrual phase with high internal consistency, sum of responses to 28 of 30 possible items each scored 0 to 3 points with total scoring (0=no symptoms, 84=most severe).
over duration of treatment from baseline to visit 5, including 4 menstrual cycles averaging 4 months after baseline visit No
Secondary Proportion of Patients With PMTS Visit-wise Response to Treatment (50% Improvement) Visit-wise response considers participants who remained in the study until Visit 5 and provided data for the visit. PMTS = Premenstrual Tension Syndrome (Observer Rating) Scale: a clinician-administered retrospective scale developed for the study of PMS, a sum of responses to 10 items each with 4 points (0=no symptoms, 40=most severe). over duration of treatment from baseline to visit 5, including 4 menstrual cycles averaging 4 months after baseline visit No
See also
  Status Clinical Trial Phase
Completed NCT02481973 - The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome Phase 2
Completed NCT00195559 - Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder Phase 3
Completed NCT00048854 - Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder Phase 1/Phase 2
Completed NCT05349344 - Effect of Aerobic Exercise on Premenstrual Syndrome Symptoms (PMS). N/A
Recruiting NCT06146673 - A Multidimensional Study of Premenstrual Syndrome and Body Image
Recruiting NCT05836454 - The Soft Tissue Mobilization Techniques on PMS N/A
Completed NCT05499000 - The Effect of Emotional Freedom Technique on Premenstrual Syndrome N/A
Recruiting NCT06144073 - The Effect of Mandala Art Therapy in Coping With Premenstrual Syndrome N/A
Recruiting NCT06105567 - The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress N/A
Completed NCT03298607 - The Impact of Serelys PMS on Symptoms of PMS Phase 3
Recruiting NCT06176313 - Effects of Training Given to Cope With Premenstrual Syndrome and Mandala Activity on Premenstrual Symptoms N/A
Recruiting NCT02562053 - Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? Phase 3
Completed NCT00229346 - Fibromyalgia and Psychiatric Symptoms Among PMS and PMDD Patients N/A
Completed NCT00516113 - A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria Phase 4
Completed NCT04901598 - Physical Activity Level, Aerobic Capacity and Dietary Habits Among a Cohort of Females With Premenstrual Syndrome
Completed NCT05692479 - Premenstrual Syndrome and Physical Activity Self-Worth
Not yet recruiting NCT06052722 - The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders N/A
Completed NCT05665972 - Effects of Mandala Coloring on Premenstrual Syndrome N/A
Completed NCT05556252 - The Effect of Hydrogen-rich Water on Premenstrual Symptoms and Quality of Life N/A
Completed NCT05725447 - Cross-cultural Adaptation, Validity and Reliability of the Turkish Version of the Premenstrual Syndrome Impact Questionnaire (PMS-IQ)